News|Articles|September 23, 2026

ASTRO 2026 Preview: Pancreatic SBRT, Radiosurgery for Depression, and More

Fact checked by: Russ Conroy

Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.

The upcoming 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will feature data spanning nearly every corner of the specialty, from randomized comparisons of stereotactic and conventionally fractionated radiation in pancreatic cancer to emerging uses of radiation medicine outside of oncology. Ahead of the meeting, Beth Erickson, MD, FACR, FASTRO, FABS; Brandon Mancini, MD, MBA, FACRO; and William Chen, MD, shared with CancerNetwork® the presentations they are most eager to see.

Related to this article

3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 3rd, 2026

AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer

In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.

A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.

November 9th, 2026

Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC

A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.

Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.

November 8th, 2026

Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer

Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.

November 6th, 2026

Training, Invasiveness, and Workload Behind Falling Prostate Brachytherapy Use

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

November 5th, 2026

Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

November 5th, 2026

Evaluating Factors That Affect HDR Brachytherapy and SBRT Decisions in Radiation Oncology

Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence and the data that shaped his approach.

November 4th, 2026

Setting Up an HDR Brachytherapy Program Amid a National Decline

Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.

November 4th, 2026

16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer

In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.